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ABSTRACT
Objective: Conventional standard gamble and time trade-off methods
may be inappropriate for eliciting preferences for some health states
because both require subjects to make trade-offs between a morbid health
state and death. Thus, the objective of this study is to demonstrate the use
of conjoint analysis to obtain time trade-off estimates of healthy-year
equivalents (HYEs) for clinically relevant durations and severities of acute,
self-limiting, or nonfatal conditions such as vasomotor symptoms.
Methods: A self-administered, web-enabled, graded-pairs conjoint-
analysis survey was developed to elicit women’s preferences for reducing
the frequency and severity of vasomotor symptoms (daytime hot ﬂushes
and night sweats). Observed trade-offs between symptom duration and
symptom relief were used to calculate HYEs for different severities and
durations of vasomotor symptoms.
Results: A total of 523 women with a mean age of 52 years completed
the survey. For these women, an improvement from severe to moderate
vasomotor symptoms yields a gain of 4.44 HYEs, and an improvement
from moderate to mild vasomotor symptoms over 1 year yields a gain of
4.62 HYEs over a period of 7 years. HYE gains for symptom relief are
larger for younger women than for older women.
Conclusions: Conjoint analysis is a feasible method for estimating HYEs
for acute, self-limiting, or nonfatal conditions. This approach may
provide an alternative utility-elicitation method when conventional stan-
dard gamble and time trade-off methods are inappropriate to the deci-
sion context.
Keywords: conjoint analysis, health-state utility, trade-offs, utility assess-
ment, satisfaction, women’s health.
Background
Quality-adjusted life years (QALYs) provide a common metric
for measuring health impacts of diseases and their treatments.
They integrate mortality, morbidity, and preferences into a single
index number representing the equivalent years of perfect health.
QALYs require estimates of health-state utilities, which are
values between zero and 1 that indicate the relative importance
or seriousness of health outcomes. Aggregating utilities over time
and affected individuals yields the number of QALYs achieved by
a particular health-care intervention. This index of health-care
beneﬁts is widely used in cost-utility analysis for evaluating
health-care investments and in guiding formulary and reimburse-
ment decision-making.
Although health-state utility estimates have proven useful for
evaluating a wide range of diseases, obtaining and interpreting
health-state utilities for acute, self-limiting, or nonfatal conditions
can be problematic. For example, Bala and Zarkin evaluate the
utility gain from using anesthesia in a 1-hour root-canal operation
[1]. Scaling a health-state utility for chronic pain from a year to an
hour yields a QALY gain for anesthesia of about 0.0001. Using a
cost-effectiveness threshold of $40,000 per QALY yields a corre-
sponding societal value of about $4.Clearly, dental patientswould
pay far more than $4 to avoid an hour of intense pain, suggesting
the QALY gains of anesthesia based on chronic-pain health-state
utility estimates are inappropriate in this application. Methods
commonly used to estimate health-state utilities for chronic con-
ditionsmay be of limited use in obtaining valid estimates for acute,
self-limiting, or nonfatal conditions. Researchers therefore
employ somewhat ad hoc procedures such as “chaining” to derive
QALYs for these conditions [2–4].
Health-state utility elicitation methods include visual analog
scale (VAS), standard gamble (SG), and time trade-off (TTO).
Most visual analog or “thermometer” scales ask subjects to rate
a speciﬁed health state on a scale ranging from death to full
health. Although the rating scale is easy to administer, it involves
no trade-offs among health states or between health states and
time. Thus, this method has no basis in utility theory [5].
Standard gamble, which is derived from von Neumann and
Morgenstern’s theory of utility under uncertainty, is a method for
eliciting theoretically consistent utility estimates [6]. Subjects
choose between a pair of health states A and B, in which A
represents a chronic condition of less-than-perfect health and B is
a gamble between perfect health with probability P or instanta-
neous painless death with probability 1 to P. The value of P that
leaves subjects indifferent between the certain and probabilistic
alternatives is the utility of the certain condition. Unfortunately,
many subjects are reluctant to accept trade-offs between mortal-
ity risks and acute, self-limiting conditions [7]. SG methods also
suffer from the limitation that subjects must evaluate potentially
small probabilities of a clinically implausible outcome, that is,
instantaneous painless death. The fact that most people have
poorly developed computational skills and have difﬁculty
working with probabilities is well known [8,9].
Because subjects may ﬁnd the SG elicitation format difﬁcult,
many researchers employ the TTO elicitation format [10]. Sub-
jects evaluate living the remainder of their life in an impaired
health state versus living a shorter number of years in full health.
TTO appears to be an easier task than SG for subjects, but
longevity trade-offs also may be unacceptable for acute condi-
tions where reduced life expectancy is not a clinically relevant
outcome. All health-state preference elicitation methods require
deﬁning the duration of the condition, most commonly as “the
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rest of your life.” The TTO method explicitly relies on well-
deﬁned health-state-duration preferences to quantify the relative
seriousness of the condition. To simplify using preference esti-
mates in health-economic evaluations, analysts conventionally
apply health-state utility estimates to independent time periods.
Although all health-state preference elicitation methods incorpo-
rate positive time preference to some degree, the TTO method is
especially vulnerable to this phenomenon because it is explicitly
based on time preference logic. Although in and or itself, capturing
positive time preference in health-state utility elicitation is not a
problem, applying positive-preference health-state utility esti-
mates to independent time periods, as is commonly performed in
the estimation of QALYs in health economic evaluations, can
confound the results of such studies. This problem is exacerbated
when analysts apply discounting to health effects and thus double-
count time preference in their models [11].
The objective of this study is to demonstrate a practical
method of obtaining healthy-year equivalents (HYEs) as an alter-
native measure of the value of treatments for acute, self-limiting,
or nonfatal conditions [12–14]. HYEs, like QALYs, measure
perfect-health time equivalents for a given condition; however,
unlike QALYs, HYEs do not require that a health state is inde-
pendent of the time spent in that health state. Rather, the quality-
adjusted time equivalence is obtained directly for speciﬁed
outcome durations. Although HYEs avoid restrictive assump-
tions required to estimate health-state utilities, the HYE method
has not gained acceptance because it requires obtaining a sepa-
rate utility estimate for each possible duration of a given health
condition. This study demonstrates the feasibility of using readily
available conjoint-analysis methods to obtain duration-speciﬁc
TTOs for clinically relevant durations of acute vasomotor symp-
toms associated with menopause.
Conceptual Framework
Conjoint-analysis methods have been widely used and validated
in marketing research, transportation, and environmental eco-
nomics [15–19]. Conjoint analysis, as applied to health-care
decision-making, is a systematic method of eliciting trade-offs to
quantify the relative levels of satisfaction people assign to various
treatment attributes. It is based on the premise that medical
interventions are composed of a set of features or attributes and
that the attractiveness of a particular intervention to an indi-
vidual is a function of these attributes [20]. Conjoint analysis is
increasingly used in health economics to calculate patients’ and
physicians’ stated preferences for health-care interventions, treat-
ment alternatives, and health-care services (see Ryan and Gerard
[21] for a recent review of health applications).
Conjoint-analysis surveys yield discrete-choice data. The
random utility model (RUM) has been used extensively in ana-
lyzing individual choice data [22]. RUMs assume the conjoint
utility associated with a particular alternative is expressed as a
function of the attributes of the alternatives. The conjoint utility
of individual i from alternative j is:
U V X Zij ij ij i i ij= ( ) +, , b e (1)
V indicates the deterministic part of the utility function and e
denotes a random error term. X is a vector of treatment or
symptom attributes, Z is a vector of individual characteristics,
and b is a vector of marginal-utility parameters.
Unlike SG and TTO health-state utilities that are anchored
by zero and 1, conjoint utilities are deﬁned on an interval
scale. Therefore, only relative differences in conjoint utilities are
meaningful. Conjoint marginal utilities, or partworths, can be
used to indicate subjects’ willingness to trade symptom severity
for symptom duration. Deﬁne total conjoint utility for a health
proﬁle described by a period of less-than-perfect health combined
with a period of good or normal health as:
U U H T H T Tk k k o k= ( ) −( )[ ], , , (2)
where Hk is a set of symptoms, Tk < T¯ is the symptom duration,
T¯ is a clinically relevant maximum symptom period, Ho is good
health and T¯ - Tk is the duration of good health in the proﬁle.
We are interested in ﬁnding the time-equivalent duration in good
health, HYE that provides the same conjoint utility U¯ as a given
symptom proﬁle:
U H U H T H T To k k o k, , , ,HYE( ) = ( ) −( )[ ] (3)
Figure 1 illustrates the relationship between time equivalence
and conjoint utility for combined durations of both symptoms
and normal or perfect health over a clinically relevant time
period T¯ .
In general, we are interested in the change in HYEs for
clinically relevant symptom improvements. Using Eq. 3 and
solving for DHYE for an improvement from health proﬁle j to
health proﬁle k:
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Equation 4 is a straightforward analog to calculating
ex-post willingness to pay when the conjoint task involves
money trade-offs instead of TTOs (when trade-offs involve
risks, a similar welfare analog can be calculated in terms of
maximum acceptable risk) [23]. If conjoint utility is linear in
parameters, and holding individual characteristics Z in Eq. 1
constant, then
U H T H T T X T X T Tk k o k k i k o i k, , ,1( ) −( )[ ] = ⋅ + ⋅ −( )∑ ∑b b
(5)
Figure 1 Healthy-year equivalence of ill-health proﬁle k. HYE is the length of
time with no symptoms that yields the same conjoint utility as some combi-
nation of symptom years and symptom-free years over a clinically relevant time
period T¯. HYE, healthy-year equivalent.
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And Eq. 4 becomes:
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Calculating DHYE using Eq. 4 for nonlinear utility speciﬁcations
may require numerical approximations.
Application toVasomotor Symptoms
Survey Instrument
We developed a graded-pairs conjoint-analysis survey that incor-
porates the most salient attributes of vasomotor symptoms. The
attributes were determined from a review of the literature and
consultations with a medical expert, a health economist, and a
psychologist with extensive experience in clinical trials of
hormone-replacement therapy (HRT) for the treatment of vaso-
motor symptoms. Although we used input from these advisors in
the development of the attributes and levels, we did not seek
formal consensus. Based on this information, we included the
following characteristics of vasomotor symptoms: severity and
frequency of daytime hot ﬂushes, frequency of night sweats, and
duration of symptoms.
The maximum duration of symptoms included in the study
was 7 years. This duration was chosen to represent a clinically
meaningful duration for an acute, self-limiting condition such as
vasomotor symptoms. We consulted the literature on the epide-
miology of vasomotor symptoms. The mean duration of vaso-
motor symptoms is 2 to 3 years. Nevertheless, 60% of women
experience hot ﬂushes for up to 5 to 7 years [24].
In addition to symptom attributes, the survey included
10-year risks of serious adverse events, including risk of hip or
back fractures, risk of heart infarct, and risk of breast cancer.
Adverse event risks were used to address a separate survey objec-
tive and are presented elsewhere [25]. Table 1 lists the treatment
attributes and levels used in the survey.
The survey was ﬁnalized after conducting two sets of pretest
interviews. Sixteen women completed interviews using a
“think-aloud” protocol. Interviews lasted between 45 and 75
minutes, depending on the responsiveness of the subject. Some
of the pretest interview subjects had difﬁculty completing con-
joint tasks with three alternatives. Thus, to obtain more real-
istic and reliable responses, the conjoint tasks were revised to
include only two, rather than three, treatment options. The
question format was changed from choice to rating (graded-
pairs) to improve the power of the two-alternative format. The
ﬁnal survey consisted of a series of paired treatment compari-
sons created by assigning different levels to corresponding pairs
of treatment attributes. The study was reviewed and approved
by the Ofﬁce of Research Protection and Ethics at Research
Triangle Institute.
Subjects were asked to assume that they were seeking treat-
ment for severe and frequent vasomotor symptoms and that only
two treatments were available. Relative treatment preferences
were indicated using a 5-point scale. Risk levels were described
using relative and absolute scales in separate versions of the
survey instrument (see Table 1). Figure 2 is an example trade-off
task stated in absolute terms. We report only the symptom sever-
ity and duration trade-off results here.
The experimental design combined speciﬁc attribute levels to
describe a set of hypothetical treatment proﬁles. These proﬁles
were paired to provide statistically efﬁcient comparison sets for
the trade-off tasks. We employed a variation of a commonly used
algorithm to construct a near-optimal experimental design using
27 treatment-pair trade-off tasks [26–28].
Survey Sample
Survey subjects were recruited from Harris Interactive’s Con-
sumer Panel via email [29]. Women aged 46 to 60 years and
residing in the United States were eligible to participate after
providing written informed consent. The survey instrument was
accessed via a secure internet site. Subjects had unlimited time to
complete the survey but could not return to previously completed
trade-off tasks or other sections of the survey.
Empirical Model
The conjoint utility of a given treatment outcome k is a function
of the categorical b coefﬁcients for symptom severity, symptom
frequency, and 10-year risks of serious adverse events. Because
preferences for the frequency and severity of daytime hot ﬂushes
and night sweats may depend on duration, we speciﬁed efﬁcacy
as interaction terms between vasomotor symptom attributes and
duration. Duration also was included independently in the model
as a linear, continuous covariate. Thus, the empirical speciﬁca-
tion for utility Vk is:
V Tk T kk k k
k
= + + +( )⋅ +
+
b b b b
b b
Severity DayFreq NightFreq
HipRisk HeartRisk CancerRiskk k+ b (6)
Table 1 Attributes and levels for HRT for the relief of vasomotor
symptoms
Treatment feature Levels
Severity of daytime hot
ﬂushes
 No daytime hot ﬂushes
 Mild: a ﬂeeting warm sensation with no
sweating that does not disrupt normal daily
activity
 Moderate: a warm sensation with sweating
that does not disrupt normal daily activity
 Severe: a hot sensation with sweating that can
disrupt normal daily activity
Frequency of daytime
hot ﬂushes
 None (0 times) during the daytime
 1–2 times during the daytime
 3–6 times during the daytime
 More than 6 times during the daytime
Frequency of night
sweats
 None (0 times) per night
 1–3 times per night
 4 or more times per night
Duration of hot ﬂushes
and night sweats
 1 year
 2 years
 4 years
 7 or more years
10-year risk of hip or
back fracture
 15/1000 (1.5%) or 50% reduction
 30/1000 (3%) or no change
10-year risk of heart
infarct
 38/1000 (3.8%) or 25% reduction
 50/1000 (5%) or no change
 65/1000 (6.5%) or 30% increase
10-year risk of breast
cancer
 23/1000 (2.3%) or 25% reduction
 3/1000 (3%) or no change
 39/1000 (3.9%) or 30% increase
HRT, hormone-replacement therapy.
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where T is symptom duration in years.
Severity is symptom severity level.
DayFreq is number of hot ﬂushes per day.
NightFreq is number of night sweats per night.
HipRisk is relative or absolute risk of fracture.
HeartRisk is relative or absolute risk of heart attack.
CancerRisk is relative or absolute risk of breast cancer.
The different treatments of risk levels as relative and absolute
were controlled for in our estimates. Nevertheless, we report only
the main-effects risk variables in this model because we are only
interested in efﬁcacy variables which depend on duration.
Because each subject provided responses to multiple trade-off
questions, we estimated a random-effects panel model to account
for within-subject rating correlation.
We used multivariate, ordered-probit regression to estimate
conjoint utility parameters for each attribute level, while control-
ling for subject demographics and other characteristics [30].
Ordered-probit estimation is the appropriate procedure for
ordered category data because it does not require that intervals
between rating categories be equal. Estimating continuous vari-
ables as categorical avoids the requirement of assuming any
particular functional form. All statistical analyses were con-
ducted using Stata version 8.2 (StataCorp, College Station, TX,
USA).
The maximum duration of symptoms included in the survey
was 7 years. The shortest duration of symptoms included in the
study was 1 year. Normal health is deﬁned as no symptoms for
the full 7-year period. The worst health state is severe vasomotor
symptoms for the full 7-year period where severe vasomotor
symptoms are deﬁned as severe daytime hot ﬂushes more than six
times per day and night sweats more than six times per night,
on average. Thus, the HYEs estimated in this study represent
changes in HYE relative to 7 years of severe vasomotor
symptoms.
Results
Study Population
Demographic characteristics for the 523 women who were eli-
gible to participate, provided written informed consent, and
completed the web-enabled survey are provided in Table 2.
Average age among the sample group was 52 years. Most women
reported that they currently experienced menopause (n = 247,
47%) or had experienced menopause in the past (n = 142, 27%).
Of these, the majority experienced moderately severe symptoms,
including hot ﬂushes one to two times per day and/or night
sweats one to three times per night, and reported experiencing
symptoms for 3 years or less.
Partworth Estimates
The rescaled partworth estimates and 5% conﬁdence intervals
for efﬁcacy attributes for 1 year are presented graphically in
Figure 3. The length of the line segments between the best and
worst levels of an attribute indicates the relative importance of
that attribute. Among the efﬁcacy attributes, the severity of
daytime hot ﬂushes is the most important attribute with a score
of 10, and is followed by the frequency of daytime hot ﬂushes
and the frequency of night sweats, respectively.
Figure 3 indicates that estimated partworths are consistent
with the natural ordering of the categories, so no symptoms or
Considering the different results and risks associated with Treatments A and B, which would 
you prefer if these were the only options available?
Results of Treatment A Results of Treatment B 
Intensity of daytime 
hot flushes 
Mild Severe 
Frequency of daytime 
hot flushes 
More than 6 times a day  
Frequency of  
night sweats 
None1–3 times a night
Duration of  
hot flushes and night 
sweats 
 7 years  2 years  
Risk of hip or back 
fractures within 10 years     50% decrease in risk     50% decrease in risk 
Risk of heart attack 
within 10 years 
   25% decrease in risk     30% increase in risk 
Risk of breast cancer 
within 10 years 
 No change in risk     25% decrease in risk  
Check the box that 
best describes your 
opinion A is 
much
better 
A is 
somewhat
better 
A and B 
are the 
same
B is 
somewhat
better 
B is 
much 
better 
1–2 times a day 
Figure 2 Example trade-off task.
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milder symptoms and fewer symptoms of each type generally
have signiﬁcantly higher utility values than less attractive out-
comes. These results indicate that subjects understood the
natural ordering of attribute levels and could discriminate effec-
tively among them.
HYEs
Table 3 presents HYEs relative to severe vasomotor symptoms
for three different levels of vasomotor symptom frequency and
severity. An improvement from severe to moderate vasomotor
symptoms (each lasting the full 7-year period) yields a gain of
4.44 HYEs. An improvement from severe to mild vasomotor
symptoms (each lasting the full 7-year period) yields a gain of
6.91 HYEs. As the symptom duration decreases, so do the gains
in HYEs. Speciﬁcally, for vasomotor symptoms lasting only 1
year, with normal health or no symptoms for the remaining 6
years during the time period, an improvement from severe to
moderate symptoms yields 0.63 HYEs and an improvement from
severe to mild symptoms yields 0.99 HYEs.
Stated preferences for vasomotor-symptom treatments may
vary depending on subject-speciﬁc characteristics. We conducted
likelihood-ratio tests results on split-samples deﬁned by subject
characteristics including menopause experience, severity of
current symptoms, duration of symptoms, education, race, and
income. Although there are signiﬁcant differences in all of the
split-sample models (P < 0.05), differences between younger and
older women were the most dramatic (P < 0.0005). Thus, we
present the results of separate preference models for younger
(52 years) and older (>52 years) (Table 4). HYE gains are
smaller for younger women for all improvements in vasomotor
symptoms, but these differences are not statistically signiﬁcant.
Discussion
Our study of women’s trade-off preferences for vasomotor
symptom control yielded several results of interest. Women in
our sample were willing to trade longer durations of milder
symptoms for shorter durations of severe symptoms, indicating
that duration of menopausal symptoms is not independent of
symptom severity and frequency. Women’s past experience with
vasomotor symptoms and socioeconomic characteristics signiﬁ-
cantly affected their preferences for treatment alternatives.
Older women and/or women with menopausal experience have
larger HYE gains than younger women for the same improve-
ments in health.
We found clinically signiﬁcant preference differences between
older, more symptom-experienced women and younger, less
symptom-experienced women. Older women had better-deﬁned
preferences and higher HYEs across health states relative to
younger women. These results might suggest that younger
women experience greater beneﬁts from any given vasomotor
symptom intervention. Nevertheless, therapeutic beneﬁts depend
on changes in HYEs, not their absolute values. The distribution
of gains between age groups thus depends on the particular kinds
of improvements realized.
Our results are subject to several qualiﬁcations and limita-
tions. The potential for hypothetical bias is a common concern in
conjoint-analysis studies. Choices involving hypothetical treat-
ments do not have the same clinical, ﬁnancial, and emotional
Table 2 Demographic and treatment characteristics of survey sample
(n = 523)
Characteristic Value
Age, mean (SD), years 52 (4.37)
Race/ethnicity, n (%)
White 466 (89)
Black or African American 19 (3)
Asian or Paciﬁc Islander 1 (<1)
Native American or Alaskan native 5 (1)
Mixed racial background 5 (1)
Hispanic 13 (2)
Missing 14 (3)
Employment status, n (%)
Full-time 215 (41)
Part-time 79 (15)
Retired 52 (10)
Homemaker 113 (22)
Other 64 (12)
Years of education, mean (SD), years 14 (2.63)
Annual Income, mean (SD), $thousands 55 (46)
Menopause experience, n (%)
Have never experienced 82 (16)
Experienced in the past 142 (27)
Currently experience 247 (47)
Not sure 52 (10)
Intensity of daytime hot ﬂushes, n (%)
Mild 68 (13)
Moderate 210 (40)
Severe 71 (14)
Not applicable 174 (33)
Frequency of daytime hot ﬂushes, n (%)
1–2 times per day 182 (35)
3–6 times per day 100 (19)
More than 6 times per day 44 (8.5)
Not sure 23 (4.5)
Not applicable 174 (33)
Frequency of night sweats, n (%)
1–3 times per night 270 (52)
4 or more times per night 57 (11)
Not sure 18 (3)
Not applicable 178 (34)
Duration of hot ﬂushes and/or night sweats
(past experience), n (%)
less than 1 year 57 (11)
1–3 years 56 (11)
3–5 years 8 (1)
5–10 years 15 (3)
More than 10 years 5 (1)
Not applicable 382 (73)
Duration of hot ﬂushes and/or night sweats
(current experience), n (%)
Less than 1 year 45 (9)
1–3 years 93 (18)
3–5 years 35 (7)
5–10 years 49 (9)
More than 10 years 23 (4)
Not applicable 278 (53)
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Figure 3 Scaled partworth estimates.
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consequences of actual treatments. The women in our study
evaluated hypothetical improvements in vasomotor symptoms
relative to a severe reference condition. Although the hypotheti-
cal outcomes and durations were clinically relevant, some sub-
jects may have found it difﬁcult to imagine health states that they
had not experienced. Nevertheless, possible measurement error
did not manifest itself in the form of systematic departure from
theoretically valid choice patterns. Parameter estimates also were
well-ordered and generally signiﬁcantly different than one
another.
Our sample was drawn from a large consumer panel used for
market research and political polling. The panel is not strictly
representative of the general population.Minorities are somewhat
underrepresented and the sample is somewhat better educated and
has higher income than the general population. The statistical
analysis presented here employs demographic weighting to
account for possible oversampling, or undersampling of particular
groups relative to the general population. Data were weighted to
reﬂect the national population of women aged 46 to 60 years for
key demographic variables including age, race and ethnicity,
geographic region, education, and income. Demographic weights
were based on US Census data obtained from the March 2004
Current Population Survey [31]. It is important to note, however,
that the prevalence of hormone replacement therapy use is higher
among nonhispanic white women, more educated women, and
women with higher incomes [32]. Our sample thus may be more
representative of women likely to seek treatment for vasomotor
symptoms.
The results of this study likely are sensitive to the maximum
duration of symptoms deﬁned in the study and are thus not
generalizable to other conditions for which a different duration
of symptoms may be appropriate. In addition, to be generalizable
across conditions, the best level of each attribute should be
deﬁned so that the combination of these levels corresponds to an
asymptomatic health state comparable to perfect health and the
survey includes a mortality risk attribute. Although we include
an asymptomatic health state, the absence of death in this
approach represents a systematic departure of this method from
conventional health-state utility estimation.
The speciﬁcation of health states and longevity in any health-
utility analysis has implications for the interpretation and gener-
alizability of the results. In a conjoint analysis, what are
considered to be clinically relevant levels and ranges of levels of
each attribute are condition-speciﬁc and some may disagree as to
whether any given set of attribute levels is appropriate to describe
the condition. The effect of different speciﬁcations of attributes
and attribute levels on utility estimation is impossible to deter-
mine without conducting a study that compares directly two or
more alternative speciﬁcations. It is important to note that,
however, the same is true for any method of health-state utility
elicitation or evaluation.
Other studies have estimated the impact of vasomotor symp-
toms on health-state utility. In one of the earliest studies of the
cost-effectiveness of hormone replacement to treat vasomotor
symptoms, Weinstein et al. used the authors’ collective judgment
to determine the health-state utility impact of HRT [33]. Noting
the lack of empirical evidence inWeinstein’s approach, Daly et al.
administered a rating scale (VAS) and a TTO instrument to a
convenience sample ofwomen at a clinic in theUK [34]. Daly et al.
deﬁned mild and severe menopausal symptoms and estimated
both VAS and TTO utilities. Zethraeus et al. used the health states
deﬁned by Daly et al. with a larger sample of women [35]. The
utility impact of VMS in nearly all of these studies is large, perhaps
much larger than would be expected when compared with utility
estimates for diseases that are generally believed to have a signiﬁ-
cant impact of quality of life such as cancer. Nevertheless, our
results are consistent with earlier ﬁndings that VMS has a large
impact on women’s quality of life.
The most obvious limitation of the approach we suggest here
is its relative complexity compared to SG and TTO approaches.
Table 3 Example of DHYEs for changes in symptom severity, frequency, and duration*
Symptom duration† 1 year 3 years 7 years
Treated health state‡ Severity: moderate
Night: 1–3
Day: 3–6
6.63
(6.53–6.74)
5.90
(5.58–6.22)
4.44
(3.69–5.18)
Severity: mild
Night: none
Day: 1–2
6.99
(6.87–7.11)
6.96
(6.62–7.34)
6.91
(6.12–7.80)
*All DHYEs estimated relative to 7 years of severe symptoms.
†Symptom duration is years with symptoms; thus, symptom-free duration is 7 years less the number of years with symptoms.
‡Day, frequency of daytime hot ﬂushes (number per day); night, frequency of night sweats (number per night).
HYE, healthy-year equivalent.
Table 4 Example of age-speciﬁc DHYEs for changes in symptom severity, frequency, and duration*
Symptom duration†
Age groups
1 year 3 years
Age  52 Age > 52 Age  52 Age > 52
Treated health state‡ Severity: moderate
Night: 1–3
Day: 3–6
6.62
(6.48–6.75)
6.66
(6.46–6.89)
5.85
(5.45–6.26)
5.99
(5.37–6.67)
Severity: mild
Night: none
Day: 1–2
6.90
(6.77–7.05)
7.13
(6.94–7.41)
6.71
(6.31–7.16)
7.39
(6.81–8.23)
*All DHYEs estimated relative to 7 years of severe symptoms.
†Symptom duration is years with symptoms; thus, symptom-free duration is 7 years less the number of years with symptoms.
‡Day, frequency of daytime hot ﬂushes (number per day); night, frequency of night sweats (number per night).
HYE, healthy-year equivalent.
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Most health-state utility studies elicit trade-offs for predeﬁned
health states or apply utility function algorithms to data collected
using quality-of-life instruments. The resulting health-state utili-
ties are combined arithmetically with durations and numbers of
affected patients. The conjoint approach requires a separate time-
consuming, resource-intensive study. The study also requires
specialized skills in survey research, experimental design, and
statistical analysis.
There are three potential advantages to conjoint-based HYEs
rather than SG- or TTO-based QALYs to evaluate improvements
in acute self-limiting conditions. First, because SG and TTO
health-state utilities estimated to assess chronic conditions may
yield unrealistically small QALY gains for acute conditions. Like-
wise, it may be difﬁcult to elicit trade-offs involving instanta-
neous painless death or life expectancy for conditions for which
death is not a realistic outcome. Conjoint studies can be designed
to elicit trade-offs in clinically relevant trade-off ranges and, thus,
may avoid understating gains. Second, unlike conventional tech-
niques used to estimate QALYs, conjoint analysis can be used to
estimate interactions between symptom or disease severity and
duration. Finally, conjoint analysis does not impose linearity
assumptions that are inconsistent with neoclassical utility theory.
Despite these theoretical advantages of conjoint analysis, further
studies directly comparing the conjoint-analysis approach to esti-
mating HYEs to conventional SG and TTO approaches to esti-
mating QALYs are required to provide more deﬁnitive evidence
of the value of each of these approaches to assessing health
interventions.
Source of ﬁnancial support: This study was funded in part by a contract
with Wyeth Pharmaceuticals, Collegeville, Pennsylvania.
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